Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 3/20 | 0.43 |
| ▸ | CTSL | P07711 | 4/20 | 0.39 |
| ▸ | CTSS | P25774 | 4/20 | 0.39 |
| ▸ | CTSK | P43235 | 4/20 | 0.39 |
| ▸ | CTSV | O60911 | 2/20 | 0.39 |
| ▸ | PLAT | P00750 | 2/20 | 0.39 |
| ▸ | CTSH | P09668 | 2/20 | 0.39 |
| ▸ | CASP14 | P31944 | 2/20 | 0.39 |
| ▸ | CASP6 | P55212 | 2/20 | 0.39 |
| ▸ | CTSZ | Q9UBR2 | 2/20 | 0.39 |
| ▸ | CTSB | P07858 | 3/20 | 0.37 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.35 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.35 |
| ▸ | IDH1 | O75874 | 2/20 | 0.35 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.34 |
| ▸ | CASP4 | P49662 | 1/20 | 0.34 |
| ▸ | CASP5 | P51878 | 1/20 | 0.34 |
| ▸ | IDH2 | P48735 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4909514 | 0.86 | ADORA1 (0.50) | ACHECTSLCTSSCTSKCTSV | |
| SCHEMBL4911723 | 0.85 | CTSK (0.37) | CTSLCTSSCTSKCTSVPLAT | |
| SCHEMBL4898439 | 0.81 | KDM1A (0.52) | ACHECTSLCTSSCTSKCTSV | |
| SCHEMBL4909018 | 0.79 | ADORA1 (0.56) | ACHECTSLCTSSCTSKCTSV | |
| SCHEMBL4907005 | 0.79 | ACHE (0.41) | ACHECTSLCTSSCTSKCTSV | |
| SCHEMBL4899380 | 0.78 | ADORA1 (0.53) | ACHECTSLCTSSCTSKCTSV | |
| SCHEMBL4899212 | 0.78 | KDM1A (0.47) | ACHECTSLCTSSCTSKCTSV | |
| SCHEMBL4907067 | 0.78 | PDE4A (0.44) | ACHECTSLCTSSCTSKCTSV | |
| SCHEMBL4906201 | 0.76 | KMT2A (0.55) | ACHEADORA2BADORA1ADORA2A | |
| SCHEMBL4906255 | 0.76 | ADORA1 (0.47) | ACHECTSLCTSSCTSKCTSV |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1984377-A2 | INHIBITORS OF TNF ALPHA , PDE4 AND B-RAF, COMPOSITIONS THEREOF AND METHODS OF USE THEREWITH | Signal Pharmaceuticals LLC (US) | 2008-10-29 | — | — | EP | disclosed |
| US-20080004271-A1 | Inhibitors of TNFalpha, PDE4 and B-RAF, compositions thereof and methods of use therewith | MCKENNA JEFFREY M | 2008-01-03 | — | — | US | disclosed |
| WO-2007084560-A2 | INHIBITORS OF TNFα, PDE4 AND B-RAF, COMPOSITIONS THEREOF AND METHODS OF USE THEREWITH | SIGNAL PHARMACEUTICALS, LLC (US) | 2007-07-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080004271-A1 | Inhibitors of TNFalpha, PDE4 and B-RAF, compositions thereof and methods of use therewith | PDE4A, PDE4B, BRAF | ACHE 939/4885CTSL 3291/4885CTSS 2357/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.